Thomas G. Wiggans, Director at Jasper Therapeutics, Inc. (JSPR), bought 10,000 shares at $0.64 ($6K) on 2023-11-21, disclosed to the SEC on 2023-11-22.
Open-market purchase of $6k JSPR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Clearly above the average filing.
| Filing → |
| JSPR | BUY | 2023-11-20 | $18K | — | Filing → |
| PRDS | BUY | 2022-12-07 | $14K | — | Filing → |
| PRDS | BUY | 2022-12-05 | $39K | — | Filing → |